Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsProvidence Health Plan SAD Coverage & Prior Auth |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentProvidence Health PlanPolicy N/A

    Miscellaneous Products — Self‑Administered Drugs (SAD)

    Customize your policy alerts

    Sign up for all Providence Health Plan policy alerts

    Know when Providence Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage, prior authorization, and medical necessity for miscellaneous self-administered drugs (SAD) for Providence Health Plan commercial and Medicaid members, including transition/monitoring provisions when administration in a provider office is requested.

    Policy Summary
    PayerProvidence Health Plan
    PolicyMiscellaneous Products — Self‑Administered Drugs (SAD)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionDocument medical rationale in chart notes when requesting healthcare provider administration and follow Table 1 to determine benefit routing and prior authorization pathway.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    60standard transition (days)
    90Xolair transition (days)
    1auth duration (yr)
    Commercial, Medicaidlines of business
    JA/JBmodifier requirement
    manypharmacy benefit only

    Coverage Criteria for Provider Administration and Transition

    Criteria for healthcare provider administration

    Provider administration may be considered medically necessary when ONE of the following is met:

    History of anaphylaxis in the past five years that required epinephrine or resulted in hospitalization

    From any cause; supports in‑office administration

    Allergic reaction to requested medication: History of allergic reaction to the requested medication

    Supports in‑office administration

    Impairment preventing self-administration: Documentation that the patient has one of the following preventing self-administration: (a) mental health or cognitive changes requiring increased level of care for safe medication administration; (b) physical conditions or dexterity issues that impede clean handling and safe administration technique; (c) inability to recognize symptoms of anaphylaxis and/or to act to treat anaphylaxis appropriately; (d) needle‑phobia diagnosed by a mental health provider consistent with current DSM criteria (does not include general fear of needles)
    Policy Summary
    PayerProvidence Health Plan
    PolicyMiscellaneous Products — Self‑Administered Drugs (SAD)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionDocument medical rationale in chart notes when requesting healthcare provider administration and follow Table 1 to determine benefit routing and prior authorization pathway.
    SourceLink
    On This Page
    Coverage Criteria for Provider Administration and TransitionHCPCS / J-code Listings and Coding RulesProvider Requirements, Prior Authorization, and BillingKey Definitions and ModifiersInitiation Rules and Benefit RoutingStep Therapy and New Indication ReviewSite of Care: Home vs Provider OfficeBackground

    Each subitem is an alternative enabling provider administration

    Medical transition/monitoring

    Transition/monitoring periods when initiating certain SADs:

    Standard transition: Drugs listed as 'Medical Transition Available' are allowed a 60‑day monitoring/transition period in the provider's office to provide training in administration technique, recognition of anaphylaxis, and determination of suitability for self‑administration at home60 days

    Documented in Table 1; continuation of provider administration after transition requires meeting medical necessity criteria

    Xolair special transition: Xolair (omalizumab) initiation is allowed a 90‑day administration and monitoring period at the provider's office due to concerns for anaphylactic reactions90 days

    Explicit example in policy

    The policy specifies that subcutaneously administered drugs listed on the Usually Self-Administered list will be denied as a benefit exclusion. The Route of Administration Modifier rules require correct use of modifiers and explicitly state that subcutaneously administered drugs on that list are excluded from payment under the medical benefit. Claims for such items billed without appropriate coding may be denied per the policy's billing rules.

    Table 1 identifies multiple SAD products that are designated “Pharmacy Benefit Only”. Items so marked are intended to begin and remain under the pharmacy benefit and are not payable under the medical benefit for administration; they are therefore not subject to the SAD medical-benefit exception process. Providers should use the Table 1 benefit designation when determining the prior authorization and billing pathway for a specific product.

    The policy requires review whenever a medication is labeled for patient self-administration and a request is made for healthcare professional administration. While initial in-office administration is permitted for listed products during a defined monitoring/transition period, continuation of provider administration beyond that period is only allowed when the member meets the policy's medical necessity criteria. Relevant chart notes documenting the medical rationale for healthcare administration must be provided to support requests for continued provider-administered therapy.

    HCPCS / J-code Listings and Coding Rules

    Listed HCPCS/J codes in Table 1HCPCS
    J3490Tymlos (Abaloparatide); Strensiq (Asfotase alfa); (also used for other listed brands)
    J0129*Orencia (Abatacept) - asterisk indicates multiple routes; JA/JB required
    J0139Humira (Adalimumab)
    Q5144Idacio (Adalimumab-aacf)
    Q5141Yuflyma (Adalimumab-aaty)
    J3590Multiple brands (e.g., Hyrimoz, Yusimry, Amjevita, Hadlima, etc.)
    Q5143Cyltezo (Adalimumab-adbm)
    Q5145Abrilada (Adalimumab-afzb)
    Q5140Hulio (Adalimumab-fkjp)
    Q5142Simlandi (Adalimumab-ryvk)
    1–10 of 13
    1/2
    Listed HCPCS / J-codes for SAD itemsHCPCS
    J3590Unclassified biologics / miscellaneous J-code (used for multiple listed products)
    Q5140Hulio (adalimumab-bwwd)
    Q5142Simlandi (adalimumab-ryvk)
    J7999Tri-mix (Alprostadil, Papaverine, Phentolamine)
    J0364Apokyn (Apomorphine)
    J3490Unclassified drugs / J3490 entries for multiple listed products
    J0517Fasenra (Benralizumab)
    J0717Cimzia (Certolizumab pegol)
    J0599Haegarda (C1 esterase inhibitor)
    J0630Calcimar/Miacalcin (Calcitonin Salmon)
    1–10 of 50
    1/5
    Authorization duration
    Authorization durationAuthorization and reauthorization for coverage under the medical benefit will be approved for one year
    Reauthorization frequencyAnnual reauthorization required (every 12 months)
    Applies toCoverage under the medical benefit for listed self‑administered drugs

    Provider Requirements, Prior Authorization, and Billing

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required: Medications listed on Table 1 that require prior authorization must meet the clinical criteria in this policy. Approval of a prior authorization is for self-administration at home unless the drug is designated in Table 1 as "Medical Transition Available," in which case a limited monitoring period (60 days, or 90 days for Xolair®) at the provider's office is allowed.

    • PA approvals assume self-administration at home unless Medical Transition Available is indicated in Table 1
    • Medical Transition Available = temporary office monitoring period (60 days; 90 days for Xolair®)
    Note

    Use Table 1 to determine PA pathway

    Use Table 1 (Self‑Administered Drug List) to determine the PA pathway and benefit designation for each product. Table 1 identifies the HCPCS/J‑codes, whether a product is Pharmacy Benefit Only or Medical, and whether Medical Transition is available.

    • Follow the benefit designation in Table 1 to determine whether the drug is processed through the pharmacy benefit or as a medical benefit
    • Table 1 lists the HCPCS/J‑codes and any Medical Transition availability
    Documentation Required

    New / Off‑label Indication Review

    New or off‑label indication review: Requests for indications approved by the FDA within the previous six (6) months will be reviewed under the New Drug/Indication Awaiting P&T Review process (Prior Authorization Request ORPTCOPS047). Requests for non‑FDA (off‑label) indications must be supported by listings in AHFS, Drugdex, or NCCN and will be evaluated based on prescriber rationale, available evidence, formulary alternatives, and whether the use is experimental/investigational.

    • FDA approvals within prior 6 months → New Drug/Indication Awaiting P&T Review (ORPTCOPS047)
    • Off‑label uses require listing in AHFS, Drugdex, or NCCN and will be reviewed for evidence and medical necessity
    Billing Rule

    Coding and modifier denials

    Coding and modifier requirements: Drugs listed in Table 1 that are marked with an asterisk (*) have one HCPCS Level II code but multiple routes of administration and must be billed with the appropriate route modifier. Claims for those drugs billed without the required modifier (JA or JB) will be denied.

    • Asterisk (*) in Table 1 = single HCPCS code with multiple routes — JA or JB required
    • Claims for asterisked drugs billed without JA or JB will be denied
    Denial Risk

    Modifier‑related denial risk

    Modifier‑related denial risk: Use JA for the intravenous infusion route and JB for the subcutaneous injection route. Items requiring a specific modifier may be denied or misprocessed if billed without the correct modifier. In addition, subcutaneously administered drugs listed as Usually Self‑Administered may be excluded from benefit when billed as a medical administration without appropriate justification.

    • JA = Intravenous administration; JB = Subcutaneous administration
    • Failure to append required modifier may result in denial or erroneous processing
    • Subcutaneous drugs on the Usually Self‑Administered list may be denied as a benefit exclusion if billed as provider‑administered without justification

    Key Definitions and Modifiers

    Self-administered drugs — definition and safe administration context
    DefinitionMedications identified as medically appropriate for administration by a patient or caregiver, safely and effectively, without medical supervision
    Policy contextMany SADs are intended for self‑administration at home; the policy allows limited in‑office transition/monitoring periods for select products listed as 'Medical Transition Available'
    Documentation requiredIf provider administration is requested beyond transition period, relevant chart notes must document medical rationale for requiring healthcare professional administration
    Medical Transition Available
    Marker nameMedical Transition Available
    MeaningDesignates products allowed a limited in‑office initiation/monitoring period (see Table 1 entries with 'Medical Transition Available = X')
    Typical transition periodStandard transition period is 60 days; Xolair (omalizumab) has an extended 90‑day transition as noted elsewhere in the policy
    JA/JB modifiers
    JA modifierUse JA when billing the intravenous infusion form of the drug (required for items marked with an asterisk)
    JB modifierUse JB when billing the subcutaneous injection form of the drug (required for items marked with an asterisk)
    Denial riskClaims for asterisked J/Q codes billed without either JA or JB modifier may be denied or misprocessed

    Initiation Rules and Benefit Routing

    Initiation and benefit routing

    Initiation rules for drugs listed in Table 1

    Pharmacy Benefit Only: Drugs marked as 'Pharmacy Benefit Only' in Table 1 start under the pharmacy benefit and are not subject to SAD policy exception requirements

    These products are intended for dispensation via the pharmacy benefit and are typically self‑administered at home

    Step Therapy and New Indication Review

    Request typeReview pathway / requirementsSupporting references requiredCoverage implication
    FDA-approved indication (new within prior 6 months)Will be reviewed using the New Drug and/or Indication Awaiting P&T Review process (Prior Authorization Request ORPTCOPS047)N/A — plan review via P&T processCoverage decision deferred pending P&T review and individualized medical necessity determination
    Off‑label (non‑FDA approved) indicationRequires demonstration that the proposed indication is listed in AHFS, Drugdex, or NCCN and evaluation of prescriber medical rationale and available evidenceCitation of the specific listing in AHFS, Drugdex, or NCCN and prescriber rationale; supporting literature as availableConsidered subject to evaluation; may be denied if considered experimental/investigational
    Medicaid-specific requestsCoverage limited to conditions designated as covered line‑item numbers by the Oregon Health Services Commission (Prioritized List)Reference to the designated covered line‑item number on the Prioritized List of Health Care ServicesCoverage only if condition appears on the Prioritized List; otherwise not covered under Medicaid
    General review considerationsCoverage decisions are individualized based on medical necessity and whether the treatment is experimental/investigationalPrescriber rationale, formulary alternatives, and available published evidence are consideredMay be approved or denied following individualized determination

    Site of Care: Home vs Provider Office

    Note

    Initial administration allowed in-office during transition period (60 days; 90 days for Xolair)

    Initial administration may occur in the provider's office during the allowed medical transition/monitoring period: standard transitions listed as 'Medical Transition Available' are allowed 60 days in-office monitoring, and Xolair (omalizumab) initiation is allowed a 90-day in-office monitoring period.

    Note

    Pharmacy Benefit Only items are for pharmacy dispensing and home self-administration

    Products designated 'Pharmacy Benefit Only' in Table 1 are intended to be dispensed via the pharmacy benefit and are expected to be self-administered at home; these items start under the pharmacy benefit and are not subject to SAD medical benefit exception requirements.

    Background

    Self-administered drugs are medications identified as appropriate for safe and effective administration by a patient or caregiver without medical supervision. This policy balances patient convenience and cost containment with safety by: allowing selected products a limited in-office medical transition/monitoring period (see Table 1), requiring documentation when continued provider administration is requested, and defining clinical circumstances under which healthcare provider administration may be medically necessary.